newsfilter
← Latest News
GlobeNewswire·

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory